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1. Introduction 
Conjunctival tumors are one of the most frequent tumors of the eye and adnexa. They 
comprise a large variety of conditions, from benign lesions such as papilloma to malignant 
lesions such as epidermoid carcinoma or melanoma which may threaten visual function and 
patient´s life if not diagnosed early. Although conjunctival tumors may arise from any type 
of the conjunctival cells, epithelial and melanocytic are the most frequent origins. Epithelial 
tumors account for a third to half of all tumors, with a higher prevalence in countries with 
larger actinic exposure. Aproximately 40% of the tumors have an epithelial origin and 64.5 
% of them were pre-cancerous lesions (Saornil et al, 2009). The clinical differentiation 
between pre-cancerous benign and malign lesions is difficult, requiring a biopsy for a 
definitive diagnosis.  
Squamous neoplasia of the conjunctiva /cornea is a rare malignancy of conjunctival limbal 
stem cells, and the management of this malignancy may affect the ultimate outcome. The 
clinical distinction of  squamous conjunctival neoplasia from other amelanocytic 
conjunctival tumors is based on certain clinical features of the tumor, and its correct 
management requires an understanding of normal anatomy and histology of the cornea and 
conjunctiva, as well as knowledge of the principles of tumor management. 
Conjunctiva is a thin and flexible mucous membrane that extends from the internal 
surface of the eyelids to the fornix and anterior ocular surface up to the corneoscleral 
limbus. Histologically, conjunctiva is similar to other mucous membranes and comprises a 
non-keratinized stratified epithelium having two or more layers over the stroma formed 
by fibrovascular connective tissue containing vessels, nervous and lymphatic tissue. Basal 
layer of epithelium comprises melanocytes which produces melanine and inject it in the 
surrounding cells. Throughout the length of epithelium we can observe cup-shaped cells 
in charge of producing the mucoid component of the lacrimal film. These cells are called 
goblet cells.  
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1.1 Definition of Ocular Surface Squamous Neoplasias (OSSN) 
Squamous cell neoplasia may occur as a localized lesion confined to the surface epithelium 
(conjunctival intraepithelial neoplasia) or as a more invasive squamous cell carcinoma that 
has broken through the basement membrane and invaded the underlying stroma (Shields & 
Shields, 2004). 
Currently, the accepted term for the localized variety is conjunctival intraepithelial 
neoplasia (CIN). However, other authors prefer the terms dysplasia (mild, moderate, or 
severe) and carcinoma-in-situ.  Where there are no longer normal surface cells then the 
process may be termed carcinoma-in-situ.  Those cases where the cornea is invaded by the 
process are usually called conjunctiva-cornea intraepithelial neoplasia (CCIN).  Squamous 
neoplasia constitutes the most frequent primary malignancy of the ocular surface. 
1.1.1 Conjuntival Intraepithelial Neoplasia (CIN) 
CIN is confined to the epithelium by definition. The term CIN was suggested in 1978, 
according with the general pathologic classification of intraepithelial tumors developed 
for cervical intraepithelial neoplasia (Pizzarello & Jakobiec, 1978). CIN includes previous 
terms referred to this epithelial neoplasia such as: Bowen´s disease, Bowenoid 
epithelioma, intraepithelial epithelioma, intraepithelioma, dysplasia and carcinoma in situ 
(CIS). 
Subjective symptoms referred by the patients include: foreign body sensation, redness, 
irritation, and a growth on the ocular surface (Giaconi & Karp, 2003). 
Clinically, CIN appears as a fleshy, sessile or minimally elevated lesion usually at limbus in 
the interpalpebral fissure and less commonly in the forniceal or tarsal conjunctiva (Shields & 
Shields, 2004). The limbal lesion may extend for a variable distance into the epithelium of 
the adjacent cornea. A white plaque (leukoplakia) may occur on the surface of the lesion due 
to secondary hyperkeratosis. 
 
Fig. 1. Conjunctival intraepithelial neoplasia showing corneal invasion. 
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1.1.2 Squamous Cell Carcinoma (SCC) 
Squamous cell carcinoma is characterized by an extension of abnormal epithelial cells 
through the basement membrane to gain access to the conjunctival stroma (Shields & 
Shields, 2004). Clinically, invasive squamous cell carcinoma is similar to CIN; however, it 
may be larger and more elevated than CIN. Even though the cells of invasive squamous cell 
carcinoma gain access to the blood vessels and lymphatic channels, regional and distant 
metastases are both rather uncommon. Clinically it is very difficult to distinguish between 
CIN and SCC (Erie et al, 1986). In many occasions it is necessary to perform a biopsy. 
1.2 Incidence 
OSSN accounts for only 5% of all ocular malignancies (Lee & Hirts, 1995). CIN is the most 
common conjunctival malignancy (Grossniklaus et al, 1987). CIN occurred more 
commonly in pale-skinned groups than in more pigmented people, with an increased 
incidence in males (75%) vs females (25%), and a mean age of 60 years (Grossniklaus et al, 
1987). OSSN associated with human immunodeficiency virus (HIV) is seen at younger 
ages (average 35 years), usually not in a bulbar location, and is more aggressive from a 
clinical point of view.  Its incidence can vary from 0.13 to 1.9/100.000 inhabitants (Lee & 
Hirts, 1995), (Giaconi & Karpp, 2003), (Saornil et al, 2009). OSSN incidence varies 
geographically, increasing with closer distance to the equator. For example, Uganda has 
1.2 cases/100.000 persons/year compared to the United Kingdom with less than 0.02 
cases/100.000 persons/year. This might suggest a role of ultraviolet light exposure in the 
etiology of these tumors. US data indicate an incidence of 0.03/100.000 people/year, with 
a 6-fold increase in association with HIV infection (Sun et al, 1997), (Verma et al, 2008). 
The lesions are more common in males and elderly, with the majority occurring at the 
limbus. In Africa the incidence is changing. The tumor is more common, aggressive, more 
frequent in young persons, especially women (Ateenyi-Agaba, 1995).  This is relationed 
with the coexistence of pandemic AIDS and exposition to the human papillomavirus 
(HPV) and ultraviolet radiations. Africa has the highest prevalence of HPV infection in 
the world (with more than 25 % of women from 15 to 74 years affected), followed by 
South America (14.3%), Asia (8.7%) and Europe (5.2%) (Clifford, 2005). A study in the 
Kampala Cancer Registry in Uganda showed an increase from 6 cases of OSSN/1.000.000 
persons per year between 1970 and 1988 to 35 cases/1.000.000 persons per year in 1992  
(Ateenyi-Agaba, 1995). In Australia,  a study found that 78.5% of affected people were 
male with a mean age of 60 years (Lee & Hirst, 1997). Similarly, another study in United 
Kingdom showed that the 77% were male, being 69% of them older than 60 years 
(McKelvie et al, 2002).  Nevertheless, a study in Zimbabwe found that a 70% of patients 
were young women with a mean age of 35 years (Pola et al, 2003), while in  South Africa 
mean age was  37  years (Mahomed & Chetty, 2002).  A study in Tanzania showed that the 
45.8% of  168  conjunctival biopsies were OSSN (Poole, 1999). 
2. Etiologic factors for CIN 
To date, CIN etiology remains unclear. The most probably explanation may be multifactorial 
causes. There are many known factors which may contribute to the development of these 
neoplasias.  
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The first one is the age, with an average of 60 years ( Lee & Hirst, 1995 ). However, it ranges 
from 4 to 90 years. The second factor attributed is the UV light exposure (Lee et al, 1994). 
This justify a higher prevalence of CIN in the ecuatorial areas, as we have previously 
commented. The exposition to the petroleum products, heavy cigarrete smoking, light hair 
and ocular pigmentation have also been associated (Napora et al, 1990).  
Younger patients affected by Xeroderma pigmentosum (Herle et al, 1991) and HIV may 
show a higher incidence (Karp et al, 1996). The majority of CIN cases reported in Africa are 
HIV-positive: 71% in Uganda, 86% in Malawi (Waddell, et al 1996), 70.6% in South Africa 
(Mahomed & Chetty 2002)  and 92.3% in Zimbabwe (Porges  & Groisman 2003). On the 
other hand, the prevalence of CIN in a HIV-positive population in Kenya was 7.8%  (Chisi et 
al,  2006). These findings suggest that CIN is a marker for HIV infection. OSSN in 
HIV/AIDS patients presents at a younger age (35-40 years old) than in HIV-negative 
patients (Timm et al, 2004). Additionally, malignancy seems to be more aggressive in 
HIV/AIDS patients (Kaimbo 1998). It is unclear whether immunosuppression or HIV itself 
plays a role in this pathogenesis. Although it has been speculated about the role of HIV in 
conjunctival squamous cell carcinoma in immunosuppression and activation of oncogenic 
viruses such as HPV in the conjunctiva, thus far only oral and anogenital HPV has been 
shown to occur more frequently in HIV-positive patients (Verma et al, 2008). 
Immunosuppression itself may contribute to the carcinogenesis. Several studies have also 
demonstrated an association between immunosupression secondary to HIV infection and 
increased risk of cervical intraepithelial neoplasia (Palefsky, 1991). 
The role of HPV remains also unclear in the etiology of CIN. It has been proved the causal 
relationship between HPV type 16 and 18 and uterine cervical carcinoma (Scott el al, 2002), 
(Giaconi & Karp, 2003), (Verma et al, 2008). However, multiple studies worldwide have 
failed to document an unequivocal association of HPV with conjunctival squamous cell 
carcinoma (Tuppurainen, 1992), (Eng et al, 2002). A small study of CIN has demonstrated 
mRNA from the E6 region of HPV, which signals actively transcribed virus (Scott et al 2002). 
Furthermore, this study in United States demonstrated the lack of such mRNA from normal 
conjunctivas, whereas African case series have revealed a high prevalence of HPV DNA in 
clinically normal conjunctivas for HPV 6 and 11, but not HPV 16 and 18 were found (Verma 
et al, 2008). In controversy HPV types 16 and 18 may be detected in CIN, in non neoplasic 
lesions and in apparently healthy conjunctiva (Karcioglu & Issa, 1997). Another study in 
Thailand concluded that solar elastosis is more frequently founded in OSSN cases that in 
controls, and HPV DNA was not found in any of the specimens (Tulvatana et al, 2003).  
HPV 5 and 8 were the most common in nearly half of OSSN in a series recently reported in 
Uganda (Ateenyi-Agaba, et al 2010). The frequency was the same in infected VIH than in 
non infected VIH. HPV 5 is not reported in caucasian CIN. HPV 16 and 18 may considerer 
as disease of sexual transmission whereas HPV 5 may appear by other possible vias. It has 
been shown in cervical cancer that the high risk variants HPV 16 and HPV 18 lead to 
carcinogenesis by inactivating tumor suppressor gene products p53 and Rb in the host with 
the viral oncoproteins E6 and E7, respectively (Verma et al, 2008). Furthermore, integration 
of viral sequences into the host genome leads to the constitutive expression of E6/E7 in 
transformed cervical cells. HPV 5 show highest downregulation of basal interleukin-8 
secretion in primary human keratinocytes. This may weaken the response to UV-induced 
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damage and consecutively mutations. Given the conflicting association studies, it appears 
that UV-B radiation plays a much greater role than HPV in the etiology of CIN (Verma et al, 
2008). 
3. Clinical presentation of CIN 
The clinical presentation of CIN may be variable. There are many different pictures on the 
ocular surface that constitute a CIN. The subjective symptoms may be also variable in 
intensivity. Appart from the presence of a growth or mass in their ocular suface, patients 
may complain no symptoms. Size, color and growth may be variable in each case. The 
presence of a red eye make, sometimes, that the patient was treated as a conjunctivitis. 
Foreing body sensation, redness, or irritation may be referred many times. CIN is 
characterized  by a slowly progressive course with low malignant potential.  In general, two 
forms of CIN have been described: nodular (or well localized) and diffuse. The diffuse type 
is less common and very difficult to diagnose in early stages. This situation may be similar 
to a chronic conjunctivitis and its surgical treatment may result complicated because clinical 
borders of the lesion may be indistinguishable (Lee & Hirst, 1995), (Giaconi & Karp, 2003).  
The typical location of this slow-growing lesion is the interpalpebral limbus, but it may also 
arise in the forniceal and palpebral conjunctiva. Limbal lesions may spread onto the cornea. 
The abnormal corneal epithelium has a frosted appearance with fringed borders and usually 
demonstrates diffuse punctate staining. Flat or elevated, the lesion may appear relatively 
translucent, gelatinous, or pearly white. Secondary hyperkeratosis over the surface of the 
lesion may give rise to a white plaque-like appearance clinically named leukoplakia. Often, 
there are surrounding corkscrew-like vascular tufts. Pigmentation may be seen and the 
lesion may be clinically misdiagnosed as melanoma (Shields et al, 2008). 
The percentages of CIN that develops into SCC have not been reported in the literature. In 
cases of SCC  the tumor may reach to eye globe, the orbit and cranial extension, with vision 
loss due to a enucleation or exenteration  (Lopez-Garcia et al, 2000). Up to 4% rates of 
metastasis to cervical lymph nodes have been reported, while metastases to distance are less 
common (Bhattacharyya et al, 1997). There is not a particular simptomatology for every 
macroscopic form of CIN.  Some of the characteristic forms of presentation of precancerous 
and malignant lesions are described: 
3.1 Precancerous lesions: Actinic keratosis and conjunctival keratotic plaque 
Both lesions, impossible to differentitate clinically, consist in a white plaque on the limbal or 
bulbar conjunctiva, in the exposed interpalpebral conjunctiva. They have a low grade of 
proliferation and very few possibilities to convert into CIN or SCC. Definitive diagnosis 
consisted in the histological study  (Mauriello el al 1996), (Shields et al, 2004 ). 
3.2 Leucoplakic lesions 
Leucoplakia (white plaque) consist in a conjuctival lesion, generally at the limbus, which 
may be round or irregular. A process of keratosis is involved (Shields & Shields, 2008). 
These lesion may also extend onto the cornea. Likewise, leukoplakic lesions may appear 
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onto a very diffuse CIN (Huerva et al, 2006). Extensive leukoplakia should raise suspiction 
of invasive SCC (Shields & Shields, 2008). 
 
Fig. 2. Leukoplakic CIN, occuping conjunctiva, limbus and cornea at the interpalpebral 
fissure. Histopatology showed complete dysplasia of the epithelium. 
3.3 Papillomatous lesions 
CIN may developed simulating a sessile papilloma. The lesion consist in a fleshy red 
appearance owing numerous fine vascular channels that ramify throughtout the stroma 
beneath the epithelial surface of the lesion (Shields & Shields, 2008). The presence of 
displasic epithelial cells helps to the differential diagnosis between papilloma and CIN. In 
rare occasions papillomas may developed into a CIN. 
 
Fig. 3. CIN with papillomatous appearance at the exposed interpalpebral fissure affecting 
the limbus. 
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3.4 Fleshly lesions 
Clinically, CIN appears as a fleshy, sessile, or minimally elevated lesion usually at the 
limbus in the interpalpebral fissure and less commonly in the forniceal or palpebral 
conjunctiva. The size of extension may be variable in each case. The presence of redness may 
simulate an inflammation. Extensive cases consist in a red gelatinous mass with vascular 
dilatations that may invade superior and nasal bulbar conjunctiva, including the caruncula, 
inferior conjuctiva and fornix invading tarsal conjunctiva and even corneal extension. 
Plaques of leukoplakia may also be present.  (Erie et al, 1986), (Shields & Shields, 2004), 
(Huerva et al, 2006).  
 
 
Fig. 4. Fleshy nodular gelatinous mass involving bulbar conjunctiva and limbus. 
 
 
Fig. 5. Fleshy nodular mass at the interpalpebral bulbar conjunctiva. 
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Fig. 6. Fleshy diffuse CIN affecting the inferior fornix resembling a chronic conjunctivitis. 
 
 
Fig. 7. Nodular fleshy CIN at the caruncle. 
3.5 Corneal invasion (Conjunctiva-Cornea Intraepithelial Neoplasia) (CCIN) 
This condition is called when the fleshy or papillomatous CIN lesions invading the 
superficial cornea. The lesions are well documented at the limbus occuping different 
degrees. Generally, in the extensive cases the cornea may be invaded (Huerva et al, 2006). 
The form of invasion may be variable: nodular, frothy vascular irregular extension and 
pedunculated and may simulate other conjunctival lesions as a pterigium or pannus (Shields 
& Shields, 2008).  
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Fig. 9. CCIN. The tumor invade almost 3/4 size of the corneal surface. 
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3.6 Squamous cell carcinoma 
Clinical presentation of invasive SCC is the same that the CIN. As the CIN, it is frequently 
observed at the interpalpebral region. Definitive diagnosis is only histopathologic (Shileds & 
Shields, 2008). 
There are some different histological types with very aggressive potential effect. 
Mucoepidermoid or adenoid SSC has an epidermal component and variable quantities of 
mucin. It often presents with inflammatory signs ( Mauriello et al, 1997). Spindle cell SCC is 
composed by pleomorphic spindle cells. Both are very aggressive with high potential of 





Fig. 10. Diffuse SCC involving the whole bulbar conjunctiva. Leukoplakic plaques are also 
present. Chronic conjunctivitis may be misdiagnosed. It clinically resembles a diffuse CIN. 
For definitive diagnosis a incisional biopsy is necessary. 
4. Diferential diagnosis 
Clinical differentiation between CIN and other limbal lesions is based on characteristic 
clinical features (Erie et at, 1986).  However, it is generally admitted that the grade of 
dysplasia cannot be consistently determined on clinical inspection alone (Lee & Hirts, 1995). 
The main differential diagnoses for localized CIN include pinguecula, pterygium and 
squamous papilloma. The differential diagnosis of conjuctival amelanotic tumors includes 
CIN, invasive SCC, malignant melanoma and a variety of benign described entities, which 
include squamous papilloma, solar elastosis and epithelial hyperplasia, keratosis or reactive 
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atypia. Conjunctival pseudoepitheliomatous hyperplasia, keratoacantoma, and conjunctival 
hereditary benign intraepithelial dyskeratosis may be also considered in CIN diferential 
diagnosis (Shields & Shields, 2008).  In these cases the hyperkeratosis and inflammatory 
cells are present in the histologic samples. Solar elastosis is a pathognomonic sign in the 
pathological diagnosis of degenerative diseases of the conjunctiva such as pingueculae and 
pterygium. In a study, the clinical diagnosis of OSSN may be accurate in 89.5% of the cases 
(Tulwatana et al, 2003). Solar elastosis was found in 53.3% of OSSN cases compared to 3.3% 
of matched controls. Solar elastosis has also been identified as a risk factor for OSSN 
(Tulwatana et al, 2003). On this basis, the clinical diagnosis alone cannot distinguish benign 
conjuntival limbal tumors from OSSN or reliably exclude, albeit an uncommon diagnosis, 
amelanotic malignant melanoma. The difficulty in distinguishing clinically between 
pterygium and CIN was illustrated in a histopathological review of 533 cases of pterygium, 
in which 9.8% were shown to have evidence of dysplasia (Hirst et al, 2009). The capacity of a 
clinician to distinguish between grades of CIN, or between CIN and invasive SCC, is also 
limited (Rudkin et al, 2011). Clinical diagnosis of CIN may be increased by the use of 
exfoliation or impression cytology. However, histopathology of the excised tumor is the 
only reliable diagnostic method and it is generally accepted to be the most appropriate 
approach to  lesions presumed to be CIN. The main hazard of clinical misdiagnosis of an 
excised benign limbal lesion is exposing the patient to unnecessary surgery. For an 
experienced ocular oncologist, the misdiagnosis of localized limbal OSSN occurs in 10.5% of 
cases (Rudkin et al, 2011).  
 
(a) (b) 
Fig. 11. Images of Pterigium (a,b) with corneal invasion may resembling in some a cases a 
CIN. On the other hand in already of 10 % of the cases may show epithelial conjuntival 
atypia. 
5. Impression cytology in diagnosis of CIN 
The management of ocular surface neoplasia depends on the ability to distinguish between 
benign, preinvasive, and invasive lesions. However, follow-up of suspicious lesions by 
repeated biopsies may cause complications such as scarring, lid deformity, limbal 
deficiency, and patient discomfort. 
As it has been described, the clinical appearance of the lesion may be suggestive of CIN. 
However, a tissue biopsy is necessary to confirm the diagnosis. Because many patients with 
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primary or recurrent CIN may be treated with topical chemotherapy without surgical 
excision of the lesion, impression cytology has been used to confirm the diagnosis without 
performing histological evaluation of the excisional biopsy. Impression cytology is a simple 
technique for removing one to three superficial layers of the epithelium by applying 
collecting devices, either cellulose acetate filter papers or Biopore membrane device. Rates of 
positivity between 77 and 80% have been reported (Nolan et al, 1994), (Tole et al, 2001). The 
disadvantage is that the superficial nature of the sample, which sometimes only contains 
keratinized cells, may be falsely negative. Cytological assessment does not provide enough 
information regarding the deepest structure of the lesion, in particular, evidence of invasion. 
Abundance of surface keratin may make sampling inaccurate. Another limitation is that 
impression cytology may not distinguish in situ from minimally invasive disease, because 
only superficial cells are collected in the method. However, high-grade dysplasia in OSSN 
cytology findings have a high correlation with histology findings, and the presence of 
abundance dysplastic cells in cytology suggest preinvasive or invasive disease in 
subsequent histology (Tananuvat et al, 2008). Although impression cytology have a high 
sensitivity for the diagnosis of ocular surface squamous neoplasia, including CIN, there are 
still cases in which impression cytology  yields false negative results. The keratotic surface 
of the lesion or the presence of dysplastic cells deep within the epithelium are the reason for 
these false negative results.  Repeated consecutive applications of the collecting filter paper 
to the surface of CIN by approaching the deeper epithelium may result in higher sensitivity 
of the technique to confirm the diagnosis (Kheirkhah et al, 2011). For the diagnosis of CIN, 
the second and third applications of impression citology may be significantly more sensitive 
than the first application. Consecutive repeated applications of the filter paper resulted in a 
significant higher sensitivity due to access to deeper epithelium. Keratinizing CIN lesions 
may result in a false negative impression cytology test due to the small number of cells 
present in the sample. It seems that keratinization leads to more false negative results at first 
application and repeated sampling in this population of CIN cases is more likely to result in 
subsequent positive due to the progressive elimination of the keratotic material. 
 
(a) (b) 
Fig. 12. Impression cytology from a CIN. Papanicolaou staining. A. False negative for CIN, 
squamous superficial keratinized material (a). Atypical dysplasic squamous cells from a 
CIN. Some pleomorphic and hiperchromatic nuclei (b). 
www.intechopen.com
Conjunctival Intraepithelial Neoplasia –  
Clinical Presentation, Diagnosis and Treatment Possibilities 
 
91 
In conclusion, repeated consecutive applications of impression citology will lead to a more 
significant sensitivity for diagnosis in eyes with CIN, thereby obviating the need for 
excisional biopsy. An additional advantage of impression cytology is the preservation of 
limbal stem cells, which are located in the basal layer of the limbal epithelium and are 
responsible for renewal of corneal epithelium throughout life. In most cases of OSSN, the 
lesions affect predominantly the limbus and have a tendency to recur. Moreover, the 
technique may be used in the follow-up of patients after treatment to determine the 
recurrence of the disease, as well as the effects of treatment such as topical chemotherapy. 
6. Histopathological findings 
The definitive term of CIN or SCC corresponds to the histologic study. When the abnormal 
conjunctival epithelial cellular proliferation involves only partially the epithelium thickness 
is classified as mild CIN, a condition also called mild or moderate dysplasia. When it affects 
full thickness epithelium it is called severe CIN, a condition also called severe dysplasia. In 
these cases there may be an intact surface layer of cells. Where there are no longer normal 
surface cells then the process is termed carcinoma-in-situ. Histopathologically, mild CIN 
(dysplasia) is characterized by a partial thickness replacement of the surface epithelium by 
abnormal epithelial cells which lack of normal maturation. Severe CIN (severe dysplasia) is 
characterized by a nearly full-thickness replacement of the epithelium by similar cells. 
Carcinoma-in-situ represents full thickness replacement by abnormal epithelial cells (Shields 
& Shields, 2004). Squamous cell carcinoma is an extension of abnormal epithelial cells 
through the basement membrane to gain access to the conjunctival stroma and have grown 
in sheets or cords into the stromal tissue. A rare variant of squamous cell carcinoma of the 
conjunctiva is the mucoepidermoid carcinoma wich presents abundant mucous-secretory 
cells within cysts. Another rare variety is the spindle cell variant of squamous cell carcinoma 
that is likewise aggressive. Histopathologically, invasive squamous cell carcinoma is 




Fig. 13. Histological specimens. (a): CIN Grade 3. Total replacement of the epithelium by 
displasic cells. Hematoxilin-eosin  x 40. (b): SCC, Displasic cell islets of squamous cells after 
invading the basement membrane, presence of  keratosic perls. Hematoxilin-eosin x 10. 
www.intechopen.com
 Intraepithelial Neoplasia 
 
92
(Shields & Shields, 2004). According to the definition, CIN may be classified in four stages  
(Kheirkhah et al, 2011): 
 CIN grade I: mild dysplasia limited to the basal one third of the thickness of the 
corneal or conjunctival epithelium. 
 CIN grade II: moderate dysplasia confined to the basal two thirds of the corneal or 
conjunctival epithelium. 
 CIN grade III: or SCC in situ: severe dysplasia that may involve the entire thickness 
of the corneal or conjunctival epithelium without invading the basement 
membrane. 
 Invasive SCC: severe dysplasia with invasion through the basement membrane. 
7. Human Papilloma Virus (HPV) detection 
As it has been described in the chapter of etiologic factors, the presence of HPV in cases of 
CIN remains controversial. DNA of HPV may be detectable by in situ hybridization. HPV 
types 16 and 18, commonly detectable, in uterine cervix may also be detectable in CIN. 
However, in non neoplasic lesions and in apparently healthy conjunctiva it may also be 
detectable ( Karcioglu & Issa, 1997). In African case series there is a high prevalence of DNA 
HPV 6 and 11, but not HPV 16 and 18 (Verma et al, 2008). On the other hand, in a series 
reported recently in Uganda, HPV 5 and 8 were the most common in nearly half of OSSN 
(Ateenyi-Agaba, et al, 2010). We have detected the presence of DNA HPV type 11. It is 
possible that different HPV associated to other risk factors may contribute to the 
development of CIN.  
The presence of DNA HPV is not strictly necessary in the diagnosis of CIN. However, when 
it is possible its determination may clarify the role of these different types of virus in the 
development of CIN. 
8. Staging for conjunctival intraepithelial neoplasia 
CIN constitutes a localized malignant situation that, in absence of treatment, may growth 
progressively with possible transformation into SCC. It develops rarely metastases at 
distance or produces ocular, orbital or intraccraneal invasion. The clinical TNM 
classification of the conjunctival carcinoma is as follows (McGowan, 2009) : 
Clinical classification (TNM): 
Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor 5 mm or less in greatest dimension 
T2 Tumor more than 5 mm. in greatest dimension, without invasion of adjacent 
structures 
www.intechopen.com
Conjunctival Intraepithelial Neoplasia –  
Clinical Presentation, Diagnosis and Treatment Possibilities 
 
93 
T3 Tumor invades adjacent structures (excluding the orbit) 
T4 Tumor invades the orbit with or without further extension 
T4a Tumor invades orbital soft tissues, without bone invasion 
T4b Tumor invades bone 
T4c Tumor invades adjacent paranasal sinuses 
T4d Tumor invades brain 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
According to this classification with the difference of clinical appearance, the cases of CIN 
may be: Tis, T1 or T2, N0 and M0.  
9. Treatment 
The management of CIN or SCC of the conjunctiva varies with the extent or recurrence of 
the lesion. 
9.1 Surgical treatment 
While the extent of the lesion determines the management of lesions in the limbal area 
involves alcohol epitheliectomy for the corneal component and partial lamellar 
scleroconjunctivectomy, with wide margins (4-5 mm) for the conjunctival component 
followed by freeze-thaw cryotherapy to the remaining adjacent bulbar conjunctiva (The no 
touch technique) (Shields & Shields, 2004). In some cases, microscopically controlled 
excision (Mohs surgery) may be performed at the time of surgery to ensure tumor free 
margins (Buus et al, 1994). Those tumors in the forniceal region can be managed by wide 
local resection and cryotherapy. Following surgical excision, large conjunctival defects may 
be successfully reconstructed with transpositional conjunctival flaps, free conjunctival 
grafts, oral mucosal grafts, and amniotic membrane grafts (Gündüz et al, 2006). In all cases, 
the full conjunctival component along with the underlying Tenon’s fascia should be excised 
using the “no touch technique”. A thin lamella of underlying sclera should be removed, in 
the limbal región, when the tumor is adherent to the globe. Intraoperative mitomycine-C 
(MMC) application has also been combined with excision of ocular surface neoplasia to 
prevent postoperative recurrences (Siganos et al, 2002). However, studies show a 53% 
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recurrence rate in pathologic studies which revealed involved margins and a 5% recurrence 
rate when clear margins are confirmed (Erie et al, 1986). In extensive lesions, surgical 
excision is difficult, and additional procedures have been employed. Extensive resections in 
very extensive CIN may produce a limbal stem deficiency (Huerva et al, 2006). Adjuvant 
radiation has the potential complications of cataracts, scleral necrosis, corneal rupture, 
scarring of the cornea and conjunctiva, moderate to severe conjunctivitis, and loss of 
eyelashes (Giaconi & Karp, 2003). For those patients with extensive tumors or those tumors 
that are recurrent, treatment with topical mitomycin C, 5-fluorouracil, or interferon alfa 2b 
have been employed. 
9.2 Topical chemoteraphy 
Topical chemotherapy has a number of advantages over surgical approach. It enables to 
treat the entire ocular surface and is not dependent upon surgical margins. Primary 
treatment with a chemotherapeutic agent avoids potential complications of surgery, which 
can include scarring of the conjunctiva and cornea, limbal stem cell failure and incomplete 
excision of the lesion. Topical chemotherapics may be preferred over surgery by some 
patients, and when the patient refuse surgery, topical chemotherapics have been 
successfully used as primary treatment.  
9.2.1 Topical mitomycin C (MMC) 
For tumors with extensive involvement, where surgical removal bears significant risks for 
postoperative problems, topical MMC should have been considered for a long time. Topical 
MMC 0.02% or 0.04% 4 times daily in 7 to 14-day for two cycles (Shields & Shields, 2004) 
have been successfully employed for preoperative chemoreduction and to manage recurrent 
and residual tumors following surgical resection (Shields et al, 2002), (Frucht-Pery  et al, 
2002), (Shields et al,2005).  MMC had been effectively used to treat primary CIN,  with 
reported success rates between 85% (Wilson et al, 1997) and  100% (Frucht-Pery & 
Rozenmam, 1994), (Ramos-Lopez et al, 2004). Another large study has shown topical MMC 
to be an efficient treatment of most, but not all cases, of CIN. Tumor regrowth occurred in 
approximately 17% of cases (Frucht-Pery et al,1997).  To avoid possible complications, the 
lacrimal punctal occlusion is mandatory during topical treatment. Chemoreduction with 
MMC cycles reduced the tumor size, especially in the surrounding thinner portions, and 
allowed for a subsequent limited surgical excision in all cases (Shields et al, 2005). Possible 
complications with topical MMC include superficial punctate epitheliopathy (Shields & 
Shields, 2004), conjunctival hyperemia,  pain,  allergy,  corneal-scleral,  melting  disturbance 
of tear film stability, goblet cell loss, squamous metaplasia and limbal stem cells depletion 
(Frucht-Pery  &  Rozenmam, 1994), (Wilson et al, 1997),  (Dogru et al, 2003), (Dudney & 
Malecha, 2004), (Khong & Muecke, 2006). Edema and endothelial apoptosis have been 
observed in experimental models (Chang, 2004).  MMC toxicity seems to be dose dependent, 
occurring with the repetition of treatment cycles. Chemoreduction with topical MMC, 
followed by interferon alfa 2b (1 million IU/mL) 4 times daily, is an effective treatment in 
extensive CIN cases where surgical resection with safety margins is infeasible and corneal 
extension resection and the repetitive cycles of MMC adjunctive could cause a depletion of 
limbal stem cells and other commented side effects on the ocular surface (Huerva et al, 
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2006).  In a follow-up of 18 months, topical Cyclosporine A (0,05%) combined with topical 
low dose of MMC (0,01%) four times a day for 12 weeks after positive margins following 
surgical excision showed no recurrence of the tumor (Tunc & Erbilen, 2006). In these cases 
Cyclosporine A has been employed by the antineovascular effect on the ocular surface. 
9.2.2 5-Fluoracil (5-FU) 
Other treatment options in the management of CIN include 5-fluorouracil (5-FU). 
However, compared with MCC, the experience with this alternative treatment is limited. 
Topical 1% 5-FU drops used 4 times daily for 2 to 4 days for each cycle and repeated at 30 
to 45 day intervals have been reported. Following initial treatment, 4 patients were 
disease-free with a mean follow-up of 18.5 months. Of the 3 patients with tumor 
recurrence, 2 remained tumor-free following additional topical 5-FU treatment and 1 
patient had a persistent tumor despite additional treatment with 5-FU and became tumor-
free following treatment with topical MMC (Yeatts et al, 2000). No adverse reactions to 
pulsed treatment were reported. Another study using topical 1% 5-FU drops 4 times daily 
for 4 weeks in 8 eyes with recurrent, incompletely excised, and untreated conjunctival 
OSSN showed complete clinical regression at 3 months in all cases. OSSN recurred in 1 
patient at 6 months but this was successfully treated with another course of 5-FU (Midena 
et al, 2000). Transient toxic keratoconjunctivitis that was noticeable with this treatment. 
Short-term complications include lid toxicity in 52% of patients, keratopathy in 11% and 
epiphora in 5% (Rudkin et al, 2010). 
9.2.3 Interferon (INF) alpha 2b 
Topical MMC and 5-fluorouracil have been used to reduce recurrence rates when used as an 
adjunct to surgical escisión and as a primary treatment; however, their use can be associated 
with marked ocular surface toxicity. Topical (1.000.000 IU/ ml/ four times a day) or 
subconjuctival INF alfa 2b (3 million IU/ml/ weekly) have been employed to treat CIN. In 
general, topical INF alpha-2b is well tolerated. Subconjunctival administration presents 
more side effects as flu-like symptoms (fatigue, fever, myalgias, malaise) and mild liver 
disturbances (Huerva & Mangues, 2008). Local conjunctival injection and follicular 
conjunctivitis are the most frequently reported side effects (Schechter et al, 2002) after 
topical administration. Redness and increase of CIN volume without ocular discomfort have 
been reported in a case (Huerva el al, 2007). Fine, diffuse, clear epithelial microcysts in the 
cornea after instillation of topical interferon a-2b have recently documented in other case 
(Aldave & Nguyen, 2007). 
Topical INF alpha 2-b, sometimes combined with subconjunctival INF alpha 2-b, seems to be 
effective as primary treatment for CIN, in recurrent cases, and also in retreatment after 
recurrence when INF has been used previously for a short period of time (Huerva & 
Mangues, 2008). Approximately, 9% of CIN treated with subconjunctival and/or topical INF 
alpha 2b showed recurrences, and 33 % of  them were successfully retreated with topical 
IFN alpha 2b (Huerva & Magues, 2008). Another one (16,6%) achieved complete remission 
after intraperioperative MMC (Hawkins et al, 1999). For INF alpha 2b topical treatment, the 
average time to complete tumor response is 11 weeks (range 2-59). For INF alpha 2b 
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subconjunctival and topical treatment, the average time to complete tumor response is 5.5 
weeks (range 2-12), (Huerva & Mangues, 2008). Previous studies found the same 
observation (Karp et al, 2001). The time to clinical resolution using topical INF alpha 2-b was 
longer (11.6 weeks) that the combined intralesional and topical interferon (4.5 weeks), but 
that INF alpha 2b treatment involved fewer side effects. In general, it seems that the 
disadvantage with topical treatment is the long duration. We must emphasize the 
importance of long term follow-up for CIN patients because recurrences can occur 
anywhere from 33 days to 11.5 years (Tabin et al, 1997), although most recurrent CIN occurs 
within 2 years of initial excision (Schechter et al, 2005). 
Many surgeons add adjunctive topical therapy to their surgical regimens for larger lesions 
(Stone el al, 2005). However, all sizes of lesions could be treated with topical INF alpha as 
the primary treatment because it is an effective, non-invasive treatment alternative to 
surgery that increases quality of life with low costs (Huerva et al, 2006), (Huerva et al, 
2007), (Huerva et al, 2009). Actually, no clear consensus on the best way to manage the 
disorder has been established, because long-term, well designed studies are still needed. 
However, two recent studies have addressed the above questions and confirmed the 
effectiveness of this topical therapy for CIN. The first study (Schechter, et al, 2008) 
demonstrated total resolution of the tumor in 96.4% of cases treated with INF alfa 2b with 
a mean follow-up of 42.4 months. The second study (Sturges et al, 2008) demonstrated 
that topical treatment with INF and surgical excision have the same effectiveness as 
primary treatment for CIN for a mean follow-up of 35.6 months. The authors concluded 
that topical IFN alfa-2b and aggressive surgical excision can be considered equally 
effective as first choice for treating CIN. Topical INF alfa-2b has some advantages over 
conventional excision, including the reduction of risk to loose limbar stem cells secondary 
to surgical trauma and, thus, compromising the integrity of the ocular surface. This 
therapeutic mode can be recommended particularly for patients who reject any type of 
surgery, or mentally retarded patients in whom surgery is complicated as well as 
extended cases where an aggressive excision could cause the loss of limbar stem cells 
(Huerva, 2008).  
Topical INF or subconjunctival INF remains a controversial issue. A recent report (Karp et 
al, 2010) concluded that subconjunctival 0.5 ml injection of 3 million IU IFN alfa 2b is a 
viable medical alternative for the treatment of ocular surface squamous neoplasia (OSSN) 
with a mean  duration of follow-up of 55 months. The authors state that the advantages of 
perilesional INF alfa 2b injection include more rapid tumor resolution, ensured 
compliance, and perhaps more direct delivery to the tumor site when compared with 
topical INF drops. However, some patients may be apprehensive about receiving 
injections around the eye and may prefer eyedrops. A single weekly injection of INF may 
have better compliance than 4 eye-drops per day dosing for a mean of three months in 
many patients. Direct delivery to the tumor site may occur in well-localized lesions, while 
annular lesions or multifocal disease requires injection over the entire involved area, 
increasing the risk of conjunctival hemorrhage. By contrast, topical therapy is delivered to 
the entire ocular surface and has very good success rates. Topical therapy could be 
recommended for patients who reject any surgical procedure or those who are 
apprehensive about injections.  
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Weekly subconjunctival Pegilated INF alpha 2b might be an alternative in resistant cases of 
CIN or recurrent conjunctival papillomatosis avoiding a mutilating surgery (Tseng, 2009), 
(Karp et al, 2010). 
9.2.4 Other treatment possibilities 
Other treatment options in the management of conjuctival OSSN include topical retinoids, 
cidofovir and photodynamic therapy (PDT). Topical unguent of trans-reinoic acid (0,01%) 
showed complete resolution of CIN in 20% of cases, whereas 40% showed only partial 
response (Espana el al, 2003). This treatment may be then only adjuvant to surgery  
Regression of diffuse conjunctival CIN was demonstrated following a 6 week course of 
topical cidofovir eyedrops (2.5 mg/ml) with later residual lesion after surgical excision 
(Sherman et al, 2002).  
Following PDT, using verteporfin, a complete clinical CIN regression, supported with 
angiographic evidence, has been reported at 1 month, without any recurrence for a mean 
follow-up of 8.6 months (Barbazetto et al, 2004). Likewise, histopathological evidence 
showing tumor regression following treatment with PDT in a patient with in situ CIN has 
been reported (Sears et al, 2008).  
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The book "Intraepithelial neoplasia" is till date the most comprehensive book dedicated entirely to preinvasive
lesions of the human body. Created and published with an aim of helping clinicians to not only diagnose but
also understand the etiopathogenesis of the precursor lesions, the book also attempts to identify its molecular
and genetic mechanisms. All of the chapters contain a considerable amount of new information, with an
updated bibliographical list as well as the latest WHO classification of intraepithelial lesions that has been
included wherever needed. The text has been updated according to the latest technical advances.This book
can be described as concise, informative, logical and useful at all levels discussing thoroughly the invaluable
role of molecular diagnostics and genetic mechanisms of the intraepithelial lesions. To make the materials
easily digestive, the book is illustrated with colorful images.
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